Disclosed are antibodies that specifically inhibit VEGF binding to only
one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis
and induce tumor regression, and yet have improved safety due to their specificity.
The present invention thus provides new antibody-based compositions, methods and
combined protocols for treating cancer and other angiogenic diseases. Advantageous
immunoconjugate and prodrug compositions and methods using the new VEGF-specific
antibodies are also provided.
